Corporate presentation highlights retina gene therapy program
4D Molecular Therapeutics highlighted lead retina gene therapy 4D-150 as its main value driver, positioned for global Phase 3 in wet AMD and DME.
The program aims to replace frequent anti-VEGF injections with a one-time intravitreal AAV treatment designed for durable aflibercept expression.
PRISM Phase 2b data cited for the Phase 3 dose showed about 1 mean supplemental injection through 1 year, implying a ~365-day average interval.
The company framed wet AMD and DME as a combined approximately $14 billion branded anti-VEGF market within a roughly $16 billion retinal vascular disease category.
The pipeline also includes 4D-175 for geographic atrophy with an open IND, alongside pulmonary programs 4D-710 in CF lung disease and 4D-725 in A1AT lung disease.
FDMT•
